Riskpilot← Back to searchSign inGet full accessPharma Forte AB
ABIn liquidationOrg 5565989877Business and other management consultancy activities · NACE 7022Est. 20001 employees
Revenue 2022
—
EBITDA margin
—
+75% vs 2021
Equity ratio
99.6%
Financial strength
Net profit 2022
SEK -9K
+79% vs 2021
| Revenue | — | — |
| EBITDA | SEK -11K | +75% |
| Net profit | SEK -9K | +79% |
| Total assets | SEK 1,1M | -1% |
| Equity | SEK 1,1M | -1% |
| Employees | 1 | — |
Legal name
Pharma Forte AB
Org number
5565989877
Legal form
Aktiebolag
NACE code
7022 · Business and other management consultancy activities
Founded
10 oktober 2000
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall bedriva stöd för strukturerad läkemedelsinformation, läkemedelsförsörjning ävensom idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 49 | 0 | 0 | 0 | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 | −48 | −39 | −44 | −11 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | 1 | −48 | −39 | −44 | −11 |
| Net financials | — | — | 62 | — | 2 |
| Profit before tax | 1 | −48 | 24 | −44 | −9 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | 1 | −48 | 24 | −44 | −9 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 1 728 | 1 506 | 1 359 | 1 136 | 1 120 |
| Equity | 1 713 | 1 495 | 1 349 | 1 124 | 1 115 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 15 | 11 | 10 | 12 | 5 |
| Total debt | 15 | 11 | 10 | 12 | 5 |
EBITDA margin
-1114000.0%
This company
15.8%
Market median
-7050733% vs market
20182022
Equity ratio
99.6%
This company
38.2%
Market median
+161% vs market
20182022
Return on equity
-0.8%
This company
18.4%
Market median
-104% vs market
20182022
Net profit margin
-944300.0%
This company
8.1%
Market median
-11658125% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SA Liquidator | Liquidator | 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (4) | ||
| Board of Directors | 2022 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharma Forte AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sven Anders Oscar Ax | Liquidator | 0 companies |
| Anders Gustaf Hjalmar Manell | Board of Directors | 0 companies |
| Anders Roger Johansson | Deputy Board Member | 0 companies |
| Anna Karin Maria Adefjord | Deputy Board Member | 0 companies |
| Per Olof Manell | Board of Directors | 0 companies |